MNG87
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.598
- E2F_TARGETS+0.456
- MYC_TARGETS_V1+0.429
- DNA_REPAIR+0.367
- PROTEIN_SECRETION+0.304
- G2M_CHECKPOINT+0.285
- MYC_TARGETS_V2+0.176
- MTORC1_SIGNALING+0.127
- UNFOLDED_PROTEIN_RESPONSE+0.105
- FATTY_ACID_METABOLISM+0.099
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.551
- APICAL_SURFACE-0.533
- TNFA_SIGNALING_VIA_NFKB-0.522
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.518
- ALLOGRAFT_REJECTION-0.517
- INFLAMMATORY_RESPONSE-0.508
- IL6_JAK_STAT3_SIGNALING-0.506
- INTERFERON_GAMMA_RESPONSE-0.494
- INTERFERON_ALPHA_RESPONSE-0.457
- MYOGENESIS-0.454
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_HKZENFDA | medulloblastoma | — | 0.936 |
| 2 | BS_9NJHQE9F | medulloblastoma | — | 0.935 |
| 3 | TCGA-91-8499-01A-11R-2403-07 | — | cohortMD1 | 0.935 |
| 4 | TCGA-HD-A634-01A-11R-A28V-07 | — | — | 0.933 |
| 5 | BS_CHDGRYHJ | medulloblastoma | — | 0.931 |
| 6 | 2d8cab40-0dda-4d6d-a9ba-83a82a7e1c15 | — | — | 0.930 |
| 7 | SJEPD030948_D1.RNA-Seq | EPN | EPN Tumor | 0.929 |
| 8 | TCGA-66-2756-01A-01R-0851-07 | — | cohortA3 | 0.924 |
| 9 | C3L-00080 | — | cohortA3 | 0.924 |
| 10 | SRR4195684 | — | — | 0.923 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.598 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.456 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.429 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.367 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.304 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.285 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.176 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.127 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.105 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.099 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.090 | Inavolisib | — uncovered |
| PEROXISOME | 0.054 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.053 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.009 | Cobimetinib | — uncovered |